Meetings - The ASCO Post

PROSPER RCC: Neoadjuvant Nivolumab Prior to Nephrectomy Followed by Additional Nivolumab in Patients With Renal Cell Carcinoma

The ECOG-ACRIN Cancer Research Group presented data from PROSPER RCC (EA8143), the first randomized phase III trial of neoadjuvant immunotherapy in patients with kidney cancer, at the European Society...

Lung Cancer

Genomics/Genetics

By The ASCO Post Staff / September 2022 / ESMO Congress 2022

Researchers Examine How Air Pollution May Drive Lung Cancer in Never-Smokers

A new mechanism has been identified through which very small pollutant particles in the air may trigger lung cancer in people who have never smoked, paving the way to new prevention approaches and the...

Global Cancer Care

By The ASCO Post Staff / September 2022 / ESMO Congress 2022

ESMO and EONS Announce Launch of PrEvCan

On September 9, the European Society for Medical Oncology (ESMO), together with the European Oncology Nursing Society (EONS), announced the launch of the Europe-wide “Cancer Prevention Across Europe” ...

ESMO Congress 2022

PROSPER RCC: Neoadjuvant Nivolumab Prior to Nephrectomy Followed by Additional Nivolumab in Patients With Renal Cell Carcinoma

Researchers Examine How Air Pollution May Drive Lung Cancer in Never-Smokers

ESMO and EONS Announce Launch of PrEvCan

Addition of Hyperthermic Intraperitoneal Chemotherapy to Surgery for Recurrent Ovarian Cancer

Penpulimab Combination Therapy for First-Line Treatment of Hepatocellular Carcinoma

Global Adaptive Platform Trial for Glioblastoma to Evaluate Novel ATM Kinase Inhibitor

Healthy Women May Have Aneuploid Epithelial Cells Resembling Breast Cancer

Perioperative Toripalimab in Locoregionally Advanced Nasopharyngeal Carcinoma